Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer
J Clin Oncol Harvey et al. 24: 4963
Publisher’s Note
The November 1, 2006, article by Harvey et al entitled, “Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer” (J Clin Oncol 24:4963–4970, 2006) was published online October 10, 2006 with an error.
In the Introduction section, the third sentence of the first paragraph was given as:
“Phase III trials showed higher response rates with second-line single-agent docetaxel compared with doxorubicin (47.8% v 33.3%, respectively; P = .008),3 mitomycin plus vinblastine (30.0% v 11.6%, respectively; P < .0001),4 or methotrexate plus fluorouracil (42% v 21%, respectively; P < .001)5 but not compared with fluorouracil plus vinorelbine (38.9% v 43.0%, respectively; P = .69)6 and paclitaxel (25.0% v 32.0%, respectively; P = .1).7 ”
While it should have read:
“Phase III trials showed higher response rates with second-line single-agent docetaxel compared with doxorubicin (47.8% v 33.3%, respectively; P = .008),³ mitomycin plus vinblastine (30.0% v 11.6%, respectively; P < .0001),4 or methotrexate plus fluorouracil (42% v 21%, respectively; P < .001)5 but not compared with fluorouracil plus vinorelbine (43.0% v 38.9%, respectively; P = .69)6 and paclitaxel (32.0% v 25.0%, respectively; P = .1).7 ”
This has been corrected as of November 21, 2006.
|
